Bolt Biotherapeutics effects 1-for-20 reverse stock split

Bolt Biotherapeutics, Inc.

Reverse stock split at 1-for-20 ratio effective June 6, 2025.
Common stock begins trading on split-adjusted basis June 9, 2025 on Nasdaq under ticker BOLT.
New CUSIP number is 097702203; par value unchanged at $0.00001 per share.
No fractional shares issued; cash payment in lieu of fractional shares.
Proportionate adjustments to outstanding stock options, equity plans, and warrants.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Bolt Biotherapeutics, Inc.: Filed a Certificate of Amendment to effect a one-for-twenty reverse stock split of common stock (effective 2025-06-06).

Change: charter amendment
Effective: 2025-06-06

Exact text from the filing

On June 6, 2025, Bolt Biotherapeutics, Inc., a Delaware corporation (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Certificate of Incorporation (the “Amendment”), to effect a one-for-twenty (1:20) reverse stock split of its outstanding common stock, effective as of June 6, 2025 (the “Reverse Stock Split”).

View on SEC.gov

Browse all governance changes →

Bolt Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-25-083180

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.